MedTrace Logo

Chemotherapy-induced Lipid Profile Changes in Women With Early Breast Cancer

NCT06958783 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 56

Last updated 2025-05-30

No results posted yet for this study

Summary

Detection of changes in the lipid profile in early-stage breast cancer patients undergoing neoadjuvant or adjuvant chemotherapy with doxorubicin, cyclophosphamide, and paclitaxel.

Conditions

Interventions

OTHER

Blood lipid monitoring in breast cancer patients during chemotherapy

This intervention is distinguished by its prospective design, enrollment of a clearly defined cohort of adult female patients with newly diagnosed early-stage breast cancer (stage IB-IIIB), administration of a uniform chemotherapy regimen (doxorubicin, cyclophosphamide, paclitaxel), and standardized monitoring of fasting lipid profiles at four precisely scheduled timepoints: pre-chemotherapy, pre-paclitaxel, post-paclitaxel, and three months post-chemotherapy completion

Sponsors & Collaborators

  • Pavol Jozef Safarik University

    collaborator OTHER

  • Cancer center Stefan Kukura Hospital Michalovce

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-05
Primary Completion
2025-02-28
Completion
2025-02-28

Countries

  • Slovakia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06958783 on ClinicalTrials.gov